TRVI
Trevi TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
TRVI Profile
Trevi Therapeutics, Inc.
A clinical-stage biopharmaceutical company that develops treatments for prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis
Pharmaceutical
03/17/2011
05/07/2019
NASDAQ Stock Exchange
26
12-31
Common stock
195 Church Street, 16th Floor, New Haven, Connecticut 06510
--
Trevi Therapeutics, Inc., was incorporated under the laws of the State of Delaware on March 17, 2011. The Company is a clinical-stage biopharmaceutical company focused on developing and commercializing nalbuphine ER for the treatment of serious neuro-mediated diseases. The company is currently developing nalbuphine ER for the treatment of chronic itching, chronic cough, and levodopa-induced dyskinesia, or LID, in patients with idiopathic pulmonary fibrosis, or IPF. These conditions share a common pathophysiology, which is mediated by opioid receptors in the central and peripheral nervous systems. Due to the mechanism of action of nalbuphine as an opioid receptor modulator, the company believes it has the potential to effectively treat these diseases.
